
Methylphenidate
Methylphenidate improves core ADHD symptoms in children and adolescents and, to a lesser degree, in adults, based on large reviews of short-term trials, though one Cochrane review rated the certainty very low. Energy drinks, which add caffeine and other stimulants, and St. John's wort, for which the evidence is limited to a few adverse event reports, are the supplement and drink interactions in our database.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Children 6 and older, adolescents and adults with ADHD, and people with narcolepsy (Ritalin label), under a prescriber
Common dosing range
Set by a prescriber. The Ritalin label starts children 6 and older at 5 mg twice daily, and adults average 20 to 30 mg a day in 2 or 3 doses, with a maximum of 60 mg a day. Concerta starts at 18 mg once each morning in children and 18 or 36 mg in adults, up to 54 or 72 mg depending on age.
When to expect effects
Blood levels peaked on average about 2 hours after a 10 mg Ritalin tablet; trials measured symptom changes over days to about 12 weeks
Watch out for
Boxed warning for abuse, misuse and addiction, which can lead to overdose and death. Also raised blood pressure and heart rate, rare sudden death in people with serious heart problems, new psychotic or manic symptoms, slowed growth in children, painful prolonged erections, and dangerous blood pressure spikes with MAOIs (monoamine oxidase inhibitors).
What is it
Methylphenidate is a prescription central nervous system stimulant and a Schedule II controlled substance. It is used for attention deficit hyperactivity disorder (ADHD), and the immediate-release Ritalin label also approves it for narcolepsy. It comes in many forms: immediate-release tablets and solution (Ritalin, Methylin and generics), taken 2 or 3 times a day; long-acting tablets, capsules, chewables, liquids and dissolving tablets taken once a day (such as Concerta, Metadate CD, Quillivant XR, QuilliChew ER, Cotempla XR-ODT, Relexxii and Jornay PM, which is taken in the evening); and a skin patch (Daytrana). Concerta is approved for ADHD in people aged 6 to 65. Every methylphenidate label carries a boxed warning about abuse, misuse and addiction. This page focuses on the forms taken by mouth; the patch has some extra skin-related warnings noted below.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
ADHD in children and adolescents Limited Evidence | Moderate to large; standardized mean difference -0.78 on clinician ratings and -0.82 on teacher ratings vs placebo | Children and adolescents with a diagnosis of ADHD | Measured at about 12 weeks |
ADHD in adults Limited Evidence | Small to moderate; standardized mean difference -0.49 vs placebo on clinician ratings | Adults with a diagnosis of ADHD | Measured over about 6 to 18 weeks |
ADHD in children and adolescents
- Effect
- Moderate to large; standardized mean difference -0.78 on clinician ratings and -0.82 on teacher ratings vs placebo
- Best fit
- Children and adolescents with a diagnosis of ADHD
- Time
- Measured at about 12 weeks
ADHD in adults
- Effect
- Small to moderate; standardized mean difference -0.49 vs placebo on clinician ratings
- Best fit
- Adults with a diagnosis of ADHD
- Time
- Measured over about 6 to 18 weeks
Evidence for 2 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
ADHD in children and adolescents
Disease adjunctA 2018 network meta-analysis of 133 double-blind randomized trials found that, at about 12 weeks, methylphenidate improved clinician-rated core ADHD symptoms in children and adolescents compared with placebo (standardized mean difference -0.78, rated moderate certainty), and it was one of only two medicines that beat placebo on teachers' ratings (-0.82, rated low certainty). It was not less well tolerated than placebo in this age group. The authors recommended methylphenidate as a first choice for short-term treatment in children and adolescents. There were not enough data to judge effects at 26 or 52 weeks. Reviews disagree on how certain these short-term results are: a 2025 Cochrane review rated the evidence very low certainty.
Bottom line: In short-term trials, methylphenidate improved ADHD symptoms in children and adolescents, but reviews differ on how certain that evidence is (a 2025 Cochrane review rated it very low), and long-term evidence is thin.
Evidence is mixed
A 2025 Cochrane review of 212 trials (16,302 children and adolescents, mean age 9.8, mean treatment 28.8 days) also found improved teacher-rated symptoms (about 10.58 points on a 0 to 72 scale, above the 6.6-point minimal important difference) but rated the certainty of every outcome very low, because 191 of 212 trials were at high risk of bias and side effects make blinding hard. It found more non-serious side effects such as sleep problems and decreased appetite, and no clear effect on quality of life.
ADHD in adults
Disease adjunctIn the same 2018 network meta-analysis, methylphenidate improved clinician-rated ADHD symptoms in adults compared with placebo (standardized mean difference -0.49), a smaller effect than in children, and adults stopped it because of side effects more often than placebo (odds ratio 2.39). A 2021 Cochrane review limited to immediate-release methylphenidate in adults (10 trials, 497 people, 6 to 18 weeks) found only low- to very low-certainty evidence of benefit, with more stomach problems and loss of appetite than placebo.
Bottom line: Methylphenidate helps adult ADHD symptoms less than it helps children's, and the evidence for immediate-release forms in adults is uncertain.
Evidence is mixed
The network meta-analysis found a clear benefit in adults, while the Cochrane review of immediate-release methylphenidate found no certain evidence of benefit, mainly because of few, small, high-risk-of-bias trials.
How it works
How to take it
What to track
Bottom line: A prescriber sets the dose and form; keep caffeine modest, avoid energy drinks and alcohol, and check any supplement with your pharmacist.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Boxed warning: abuse, misuse and addiction. Methylphenidate has a high potential for abuse and misuse, which can lead to a substance use disorder including addiction; misuse and abuse can result in overdose and death, and the risk is higher with higher doses or unapproved use such as snorting or injection. The label asks prescribers to assess each person's risk before prescribing, teach safe storage and disposal, and reassess throughout treatment.
Heart risks: sudden death has been reported in people with structural heart abnormalities or other serious heart disease taking stimulants at usual doses. Stimulants raise blood pressure (about 2 to 4 mmHg on average) and heart rate (about 3 to 6 beats per minute), and some people have larger increases.
Psychiatric effects: new psychotic or manic symptoms (in about 0.1% of stimulant-treated patients in pooled trials, versus 0% on placebo), and worsening of existing psychosis. Motor and verbal tics and Tourette's syndrome can start or worsen.
Prolonged, painful erections (priapism) sometimes needing surgery; poor circulation in fingers and toes, including Raynaud's phenomenon; slowed growth in children; and eye problems including acute angle-closure glaucoma and raised eye pressure.
Concerta: not ordinarily used in people with severe narrowing of the gut, because the tablet does not change shape and rare blockages have been reported. Daytrana patch: permanent loss of skin color at or away from the patch site (chemical leukoderma), skin sensitization, and much higher absorption if the patch is heated.
Who should avoid it
- People taking any MAOI (monoamine oxidase inhibitor) or who stopped one within the last 14 days, and people allergic to methylphenidate or other ingredients (contraindicated)
- People with known heart disease or a family history of sudden death or dangerous heart rhythms need a careful heart check first; the label asks prescribers to screen everyone before starting and to monitor blood pressure and pulse
- People with psychosis, a history of depressive symptoms or a family history of suicide, bipolar disorder or depression, tics or Tourette's syndrome, or glaucoma need screening and close monitoring
- Children under 6 and adults over 65: the Concerta label does not recommend it under age 6 (higher drug levels and more side effects such as weight loss) and says it is not indicated over age 65
Pregnancy & breastfeeding
Pregnancy: the Ritalin label says published studies and postmarketing reports have not identified a drug-associated risk of major birth defects, miscarriage or problems for the mother or baby. Stimulants can narrow blood vessels and may reduce blood flow to the placenta, and premature delivery and low birth weight have been reported in mothers dependent on amphetamine. A national pregnancy registry for ADHD medicines collects outcomes. Breastfeeding: limited data from seven mothers show methylphenidate passes into breast milk, giving infants 0.16% to 0.7% of the mother's weight-adjusted dose, with no reported adverse effects on the infant and no effect on milk production; the label asks that breastfed infants be watched for agitation, poor sleep, poor feeding and reduced weight gain.
Interactions
The label says methylphenidate is contraindicated with an MAOI or within 14 days after stopping one, because the combination can cause a hypertensive crisis, with possible outcomes including death, stroke, heart attack, aortic dissection and kidney failure. Make sure every prescriber knows about both medicines.
Energy drinks contain caffeine and other stimulating ingredients. A 2021 review of energy drink interactions says additive or greater effects of caffeine with other psychostimulants are expected, and that caffeine may enhance the heart-rate and blood-pressure effects of sympathomimetic (adrenaline-like) drugs; it names drugs such as amphetamines and cocaine but does not discuss methylphenidate, and no study of energy drinks with methylphenidate is cited. Methylphenidate already raises heart rate and blood pressure, according to its label. Avoid energy drinks while taking methylphenidate, keep other caffeine modest, and talk to your prescriber or pharmacist about how much is safe for you.
The label says these anesthetics combined with methylphenidate may raise the risk of a sudden rise in blood pressure and heart rate during surgery, and advises avoiding methylphenidate on the day of surgery in people receiving them. Tell your surgeon and anesthesia team that you take methylphenidate, and ask your prescriber how to handle the dose before surgery.
The Metadate CD, Jornay PM and Quillivant XR labels say to avoid alcohol because it can speed up release of the dose; at 40% alcohol, Metadate CD released 84% of its methylphenidate in the first hour in lab testing. In small studies of healthy adults, alcohol also raised active d-methylphenidate levels (total exposure up 21% with immediate-release methylphenidate) and strengthened stimulant effects with short-acting and long-acting forms; heart rate was also higher with the short-acting form. Ask your prescriber about any drinking.
Evidence for this pair is thin. A study of US adverse event reports in children and adolescents (1997 to 2015) found two reports involving a methylphenidate product and St. John's wort in which an interaction was judged probable in one and possible in the other; report quality was poor, and the authors said more research is needed. The Metadate CD label says methylphenidate is broken down mainly by esterase enzymes and was not metabolized by cytochrome P450 enzymes in lab studies, so the liver-enzyme speed-up that St. John's wort causes with many drugs does not explain a possible interaction. Talk to your prescriber or pharmacist before adding St. John's wort or any mood supplement.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (2)
+ alcohol
highSeveral long-acting methylphenidate labels, including Metadate CD, Jornay PM and Quillivant XR, say to avoid alcohol because it can speed up release of the dose; at 40% alcohol, Metadate CD released 84% of its methylphenidate in the first hour in lab testing. In small studies of healthy adults, alcohol also raised blood levels of active d-methylphenidate (AUC up 21% with short-acting methylphenidate; second-pulse peak up 35% with a long-acting form) and significantly strengthened stimulant effects. The studies did not measure harm.
+ st. john's wort
moderateEvidence for this pair is thin. A review of US adverse event reports in children and adolescents (1997 to 2015) found two reports involving a methylphenidate product and St. John's wort; an interaction was judged probable in one and possible in the other, report quality was poor, and the authors said more research is needed. St. John's wort speeds up liver enzymes such as CYP3A4, but methylphenidate is broken down mainly by esterase enzymes and was not metabolized by cytochrome P450 enzymes in lab studies, so that effect does not explain a possible interaction. The Ritalin label lists serotonin syndrome with serotonergic drugs among rare postmarketing reports, and St. John's wort is serotonergic, but no published case with this pair was found.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I drink energy drinks while taking methylphenidate?⌄
It is best to avoid them. Energy drinks add caffeine and other stimulants on top of a medicine that already raises heart rate and blood pressure, and a review of energy drink interactions expects their effects to add up with stimulant drugs. Ask your prescriber how much caffeine is reasonable for you.
Is coffee okay with methylphenidate?⌄
Our database lists energy drinks, not coffee, as an interaction. Caffeine from any source adds stimulation, so keep it modest, watch for a racing heart, jitteriness or poor sleep, and ask your doctor or pharmacist what amount suits you.
Can I take St. John's wort with methylphenidate?⌄
Talk to your prescriber first. The evidence is limited to a small number of adverse event reports in children and adolescents, where an interaction was judged probable in one case and possible in another, and the cause is not explained by how methylphenidate is broken down. If you are looking for help with mood, your prescriber can discuss options.
Can I drink alcohol while taking methylphenidate?⌄
The Metadate CD, Jornay PM and Quillivant XR labels say to avoid alcohol, because in lab tests alcohol made the dose release faster. The Concerta label reports that alcohol up to 40% did not speed up release in the first hour in a lab test. Ask your pharmacist what your own product's label says.
Why does methylphenidate have a boxed warning?⌄
Because it has a high potential for abuse and misuse, which can lead to addiction, overdose and death, especially at higher doses or when snorted or injected. Store it locked away, never share it, and talk to your prescriber if you are worried about misuse.
References by claim
ADHD in children and adolescents
ADHD in adults
Cândido et al., 2021 · PMC (2021) link
Safety
Interaction: Energy drinks
Hladun et al., 2021 · PMC (2021) link
Interaction: St. John's wort (Hypericum perforatum)
Interaction: Alcohol
Jornay PM (methylphenidate hydrochloride extended-release) prescribing information · DailyMed (FDA label) link
Quillivant XR (methylphenidate hydrochloride extended-release oral suspension) prescribing information · DailyMed (FDA label) link
Patrick et al., 2013 · PMC (2013) link
Zhu et al., 2017 · PMC (2017) link
Track Methylphenidate with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
